Cohance Lifesciences Shares Dropped 10% After Managing Director Resignation

On October 29, 2025, Cohance Lifesciences shares dropped as much as 10%, reaching a day low of 767.10 at 10:50 AM, after opening at 844.85 on BSE. The stock has fallen 28% from its 52-week high of ₹1,121 and is down 25% year-to-date.

The fall in Cohance Lifesciences shares follows the company’s announcement that V Prasada Raju has stepped down as Managing Director and Director, effective October 28.

V Prasada Raju Resigned

In his resignation letter, Prasada Raju cited personal priorities and a desire to “continue his learning journey” as the reasons for his departure. He will remain with the company temporarily to ensure a smooth and orderly transition.

Cohance Lifesciences has named Himanshu Agarwal as Additional Director and Whole-time Director, effective October 29, pending shareholder approval. Agarwal, who currently serves as the company’s Chief Financial Officer (CFO), will hold the new position for a five-year term, according to an exchange filing. He has been the company’s CFO since January 2024.

Report from USFDA

The company has received a report from the USFDA, classifying the inspection of its facility as “Official Action Indicated (OAI)”. The company is proactively engaging with the USFDA and has launched a comprehensive remediation program to ensure the facility fully aligns with global regulatory standards. Operations at the FDF Unit-1 facility in Nacharam continue uninterrupted.

Also Read: HDFC AMC, UTI AMC & More AMC Stocks in Focus as SEBI Proposes Lower MF Expense Ratio

As previously communicated on September 18, 2025, we reiterate that in FY2025, US revenue from this formulation unit at Nacharam accounted for less than 2% of the company’s consolidated revenues, with a related EBITDA contribution below 1%. Consequently, this development is not expected to have any material impact on the company’s ongoing operations or supply commitments.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.